Aardvark said it applied to list on the Nasdaq Global Market under the symbol AARD. The company didn't give an expected size for its IPO, nor did it offer an expected price range. Morgan Stanley, B of ...

Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for PTC Therapeutics in a report ...

Ribbon Acquisition Corp successfully closed its initial public offering of 5,000,000 units, raising significant capital at a price of $10.00 per unit. The units are now listed on The NASDAQ ...

Hong Kong, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Wellchange Holding Company Limited (NASDAQ: WCT) (“Company” or the “Wellchange”), an enterprise software solution services provider headquartered in Hong ...

Dermata Therapeutics (NASDAQ:DRMA) is raising ~$2.55M in a private offering priced at-the-market under Nasdaq rules. The company is offering 2,007,880 shares of its common stock (or pre-funded ...

Looking at options history for Summit Therapeutics (NASDAQ:SMMT) we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades ...

During the last three months, 11 analysts shared their evaluations of Keros Therapeutics (NASDAQ:KROS), revealing ... state of the company. Rating: Offering insights into predictions, analysts ...

Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs to ...

NEW YORK (AP) — The following is a list of initial public offerings planned for the coming ... managed by Eddid Securities Network 1. Proposed Nasdaq symbol IOTR. Business: Singapore-based ...

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now set its financial goalposts, aiming to raise $114.4m from the initial public ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth and market share capture with its Multiple Sclerosis treatment, Briumvi. 2025 revenue guidance of $540 million ...